Taking CAR T-Cell Therapy from the Lab to the Patient Means Commercializing Where Few Have Succeeded
A Big Picture View of the Bioprinting Space from the Bottom-Up
Clinicians Are Increasingly Left with Few or even No Treatment Options
Our Understanding of the Benefits and Risks of Therapies Evolves over Time as Evidence Accumulates
Cell Culture Requirements Are Not Only Growing in Magnitude, but Shifting to Match the Increasing Use of Mammalian Cell Lines
Tools for Assessing Treatments Offer Separate, yet Promising, Potential Answers
Be sure to add firstname.lastname@example.org
to your Address Book or Safe Senders List.
here for instructions.
If you have any questions about your subscription, click
here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
© 2015 Genetic Engineering & Biotechnology News All Rights Reserved